Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
作者信息
Peter H H, Deutschmann K E, Deinhardt J, Deicher H
出版信息
Recent Results Cancer Res. 1978;68:367-74. doi: 10.1007/978-3-642-81332-0_55.
PMID:752872
Abstract
摘要
相似文献
1
Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.卡介苗（BCG）或二甲基三氮烯咪唑甲酰胺（DTIC）辅助治疗在控制II期黑色素瘤微小残留病中的价值。
Recent Results Cancer Res. 1978;68:367-74. doi: 10.1007/978-3-642-81332-0_55.
2
Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.黑色素瘤高危患者的辅助化疗和免疫治疗
Surg Gynecol Obstet. 1978 Feb;146(2):230-2.
3
Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.“高危”原发性恶性黑色素瘤辅助治疗的随机试验
Surgery. 1978 Jun;83(6):677-81.
4
Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.卡介苗免疫疗法联合达卡巴嗪（NSC-45388）治疗恶性黑色素瘤。
Cancer Treat Rep. 1976 Feb;60(2):177-82.
5
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.用二甲基三氮烯咪唑甲酰胺和卡介苗对播散性恶性黑色素瘤进行化学免疫治疗。
N Engl J Med. 1974 Sep 19;291(12):592-7. doi: 10.1056/NEJM197409192911202.
6
Adjuvant therapy in malignant melanoma: a trial of immunotherapy. chemotherapy, and combined treatment.恶性黑色素瘤的辅助治疗：免疫疗法、化疗及联合治疗的试验
Recent Results Cancer Res. 1978;68:380-6. doi: 10.1007/978-3-642-81332-0_57.
7
Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.恶性黑色素瘤手术辅助治疗中延长化疗、免疫治疗及化疗联合免疫治疗的对照研究（试验6）：初步报告
Recent Results Cancer Res. 1978;68:375-9. doi: 10.1007/978-3-642-81332-0_56.
8
Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.化疗和免疫疗法对黑色素瘤肿瘤特异性免疫的影响。
J Clin Invest. 1977 Jun;59(6):1017-26. doi: 10.1172/JCI108724.
9
Letter: Disseminated intravascular coagulation syndrome with metastatic melanoma: Remission after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC).
Ann Intern Med. 1976 Feb;84(2):175-6. doi: 10.7326/0003-4819-84-2-175.
10
A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.丙卡巴肼联合长春新碱、双氯乙基亚硝脲及咪唑甲酰胺二甲基三氮烯治疗转移性恶性黑色素瘤的临床试验
Med Pediatr Oncol. 1975;1(2):107-11. doi: 10.1002/mpo.2950010205.
引用本文的文献
1
BCG immunotherapy in stage I melanoma patients. Does it influence prognosis determined by HLA-DR expression in high-risk primary tumors?I期黑色素瘤患者的卡介苗免疫疗法。它是否会影响高危原发性肿瘤中由HLA-DR表达所决定的预后？
Cancer Immunol Immunother. 1986;23(2):155-7. doi: 10.1007/BF00199823.
Zotero 插件